# A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder

> **NCT06126653** · PHASE2 · COMPLETED · sponsor: **Aardvark Therapeutics, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** Low Dose ARD-501
- **DRUG:** High Dose ARD-501
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06126653
- **Lead sponsor:** Aardvark Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-01
- **Primary completion:** 2025-01-13
- **Final completion:** 2025-01-13
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2025-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06126653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06126653, "A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06126653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*